August 2026 Research Update

This month featured 2 single-patient reports that together show how different the Krabbe disease journey can look depending on when it is recognized and how far it has progressed. One report describes advanced disease where the focus was comfort and seizure control, while the other shows long-term stability after close monitoring from newborn screening and umbilical cord blood transplantation. Taken together, these cases add a clearer picture of why early tracking with lab markers and brain imaging can matter in research and real-world decision-making, even though individual experiences can differ widely. [1] [2]

In one case, whole exome sequencing identified two GALC gene variants that confirmed Krabbe disease, and brain imaging showed widespread white matter changes. Because the disease was already at an advanced stage, hematopoietic stem cell transplantation was not recommended, and seizures were managed with antiseizure medicines and supportive care. This illustrates that genetic testing can provide answers even late in the course, but treatment options described in the report were shaped by how far disease had progressed. [1]

In the other case, a baby identified through newborn screening had ongoing follow-up with enzyme testing, a blood marker called psychosine, and repeated brain MRI scans. Even though early development was preserved, MRI changes progressed and led to umbilical cord blood transplantation, after which enzyme activity normalized, psychosine decreased, and imaging remained stable; at age 9 the child had normal development and no seizures. The report also raised the possibility that a specific paired genetic change (Ile562Thr on the same chromosome as Tyr319Cys) might influence how the disease behaves, but this remains uncertain from a single case. [2]

These reports mainly add understanding rather than changing care for most families, because they describe only 2 individual children. They help clarify that Krabbe disease can look very different from one child to another, and that the stage of disease at the time of diagnosis can influence what approaches are considered in practice (for example, supportive seizure care versus transplant-based approaches). They also highlight that genetics, psychosine, and brain MRI can be used together to track disease in some settings, but it is still unclear how well any one child will match another child with a similar lab result or genetic finding. For now, this information is best viewed as real-world examples that may guide future research and improve counseling as more data accumulate. [1] [2]

One practical clarification from this month is that newborn screening results and early development may not tell the full story on their own, because MRI changes were an important trigger for action in the long-followed case. Another is that supportive care, including seizure control, remains a major part of care when disease is already advanced, and genetic testing can still be valuable for confirming the diagnosis. What remains uncertain is how broadly the positive long-term outcome after cord blood transplant applies, and whether the highlighted genetic haplotype reliably predicts a milder or slower course. [1] [2]